ThromboGenics Appoints Prof Dr David Guyer to its Board of Directors

ThromboGenics Appoints Prof Dr David Guyer to its Board of Directors

LEUVEN, Belgium, Dec. 20, 2013 (GLOBE NEWSWIRE) -- ThromboGenics NV (Euronext
Brussels: THR), an integrated biopharmaceutical company focused on developing
and commercializing innovative ophthalmic medicines, announces today the
appointment of Dr David Guyer to its Board of Directors.

Dr Guyer M.D.  is a long  standing member of  the US retina  community and  is 
currently the Co-Founder and Chief Executive Officer of Ophthotech Corporation
and also serves as Chairman of its board of directors. Ophthotech  Corporation 
is a public biopharmaceutical company focusing on discovering, developing  and 
commercializing first-in-class therapies for the treatment of major ophthalmic
diseases. Ophthotech's lead compound Fovista  (previously known as E10030)  is 
being evaluated in  a Phase III  trial for use  in combination with  anti-VEGF 
therapy for  the treatment  of patients  with wet  AMD. Ophthotech  listed  on 
Nasdaq in September 2013, raising $192 million in its IPO.

Dr. Guyer is also on the Boards of Allocure and Panoptica.

Dr.Guyer  co-founded   and  served   as  CEO   and  a   Director  of   Eyetech 
Pharmaceuticals, Inc., where he  led the company  through private, public  and 
corporate  financings,  and  oversaw  the  rapid  development  and  successful 
commercialization of  Macugen^® (pegaptanib  sodium), the  first  FDA-approved 
anti-VEGF pharmacological treatment for the treatment of wet AMD. Eyetech  was 
acquired by OSI Pharmaceuticals Inc for $935 million in 2005.

Staf  Van  Reet,   the  Chairman  of   ThromboGenics  commenting  on   today's 
announcement said, "I am delighted to welcome David to the Board. His  decades 
of  success  in  the  ophthalmology   space  both  in  drug  development   and 
commercialization, particularly  in  the US,  will  be extremely  valuable  to 
ThromboGenics. We are continuing to maximize the potential of JETREA^® for the
treatment of symptomatic  VMA and  further develop our  emerging portfolio  of 
therapies for the treatment of diabetes-related retinal diseases."

Dr Guyer has also  had a successful career  in academic medicine as  Professor 
and Chairman of the Department of Ophthalmology at New York University  School 
of Medicine. Dr.  Guyer received his  Bachelor of Science  (B.S.) degree  from 
Yale College summa cum laude and his medical degree (M.D.) from Johns  Hopkins 
Medical  School.   He  completed   his  ophthalmology   residency  at   Wilmer 
Ophthalmological Institute at Johns Hopkins Hospital and a retinal  fellowship 
at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.

Dr David Guyer, commenting on  his appointment, said, "ThromboGenics has  made 
significant progress in recent years, leading to the introduction of  JETREA^® 
in the US early in 2013.  I am happy to be  joining the board of this  dynamic 
company as it works to create a new treatment paradigm for patients with early
stage symptomatic VMA."

For further information please contact:

Thrombogenics

Wouter Piepers, Global Head of Corporate Communications

+32 16 75 13 10 / +32 478 33 56 32

Wouter.piepers@thrombogenics.com

Dr. Patrik De Haes, CEO

+32 16 75 13 10

Patrik.dehaes@thrombogenics.com

Chris Buyse, CFO

+32 16 75 13 10

Chris.buyse@thrombogenics.com

                          
Citigate Dewe Rogerson     The Trout Group (US investor relations)

David Dible/ Sita Shah     Todd James/ Simon Harnest

Tel: +44 20 7638 9571      Tel: +1 646 378 2926

sita.shah@citigatedr.co.uk tjames@troutgroup.com

About JETREA ^® (ocriplasmin)

JETREA^® (ocriplasmin)  is a  truncated  form of  human  plasmin. In  the  US, 
JETREA^® is  indicated  for  the  treatment of  symptomatic  VMA.  In  Europe, 
JETREA^® is  indicated  for the  treatment  of vitreomacular  traction  (VMT), 
including when  associated with  macular  hole of  diameter <  =400  microns. 
JETREA^® is a selective proteolytic  enzyme that cleaves fibronectin,  laminin 
and collagen, three major components of the vitreoretinal interface that  play 
an important role in vitreomacular adhesion.

JETREA^®has been  evaluated  in two  multi-center,  randomized,  double-masked 
Phase III trials conducted in the U.S. and Europe involving 652 patients  with 
vitreomacular adhesion. Both studies met the primary endpoint of resolution of
VMA at day 28.

JETREA's  Phase  III  program  found  that  26.5%  of  patients  treated  with 
ocriplasmin saw resolution of VMA,  compared with 10.1% of patients  receiving 
placebo (p  < 0.01).  The Phase  III  program also  showed that  JETREA^®  was 
generally well tolerated with most adverse events being transient and mild  in 
severity.

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing
and  commercializing  innovative  ophthalmic   and  oncology  medicines.   The 
Company's lead product, JETREA^®  (ocriplasmin), has been  approved by the  US 
FDA for the treatment of symptomatic VMA and was launched in January 2013. 

ThromboGenics signed a  strategic partnership  with Alcon  (Novartis) for  the 
commercialization of JETREA^® outside the United States. Under this agreement,
ThromboGenics could receive  up to  a total of  €375 million  in up-front  and 
milestone payments. It  will receive  significant royalties  from Alcon's  net 
sales of JETREA^®. ThromboGenics and Alcon  intend to share the costs  equally 
of developing JETREA^® for a number of new vitreoretinal indications.

In Europe, JETREA^® is  approved for the  treatment of vitreomacular  traction 
(VMT), including when associated  with macular hole of  diameter less than  or 
equal to 400 microns. Alcon has launched JETREA^® in the UK, Germany, Finland,
Denmark, Norway and Sweden. It has also recently introduced this novel product
in Canada.

ThromboGenics is also further  exploring anti-PIGF (Placental Growth  Factor), 
also referred  to as  TB-403, for  the treatment  of ophthalmic  and  oncology 
indications.
ThromboGenics is headquartered in Leuven, Belgium, and has offices in  Iselin, 
NJ (US)  and Dublin,  Ireland. The  Company  is listed  on the  NYSE  Euronext 
Brussels exchange  under the  symbol  THR. More  information is  available  at 
www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered  "forward-looking". 
Such forward-looking  statements  are  based  on  current  expectations,  and, 
accordingly, entail and are influenced by various risks and uncertainties. The
Company therefore  cannot  provide  any assurance  that  such  forward-looking 
statements will materialize  and does not  assume an obligation  to update  or 
revise any forward-looking statement, whether as a result of new  information, 
future events or any other reason. Additional information concerning risks and
uncertainties affecting the business and other factors that could cause actual
results to differ materially from  any forward-looking statement is  contained 
in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale  or 
purchase of securities  or assets  of ThromboGenics in  any jurisdiction.  No 
securities of ThromboGenics may  be offered or sold  within the United  States 
without registration under the U.S. Securities Act of 1933, as amended, or  in 
compliance with an exemption therefrom, and in accordance with any  applicable 
U.S. state securities laws.

HUG#1751694
 
Press spacebar to pause and continue. Press esc to stop.